Paper Review
At Pion, we develop a range of analytical instruments used for a variety of applications in the pharmaceutical space, centering around the in vitro analysis of drug and formulation candidates to optimize the drug development pipeline. Within this blog series we will look to provide brief summaries of the most recent publications to try to paint a broad picture of the application spaces in which our technologies are applied.
Most recently, Roche® utilized our SCISSOR platform to compare their reversible protein complex (RPC) formulations ([soluble protein] ≈ 250 mg/mL) to formulations methodologies typically used in biologic formulation. [1, 2] Within SCISSOR, they were able to map the release curves of each formulation, model each behavior using a range of pharmacokinetic models, and determine the effect of various post-injection phenomena.
Herein, I will give a brief summary of the paper. For additional details, please see Roche’s publication (https://www.sciencedirect.com/science/article/abs/pii/S1773224724007913.)
Contact us to learn more.
References
[1] N. Damana, P.-L. Destruel, S. Facchetti, V. Braun, V. Lebouc, Z. Marin, S. Patel and G. Scwach, "Reversible protein complexes as a promising avenue for the development of high concentration formulations of biologics," International Journal of Phharmaceutics, p. 123616, 2023.
[2] V. Braun, V. Lebouc and P.-L. D. Gregoire Schwach, "Reversible protein complexes: Advancing subcutaneous delivery with controlled and sustained release of high concentration biologics," Journal of Drug Delivery Science and Technology, p. 106122, 2024.
